Short answer
The cost to build a GMP‑grade manufacturing plant for lurasidone (brand name Latuda) can vary widely, but most estimates for a mid‑size, fully compliant facility fall in the $50 million to $200 million range. Exact figures depend on scale, location, regulatory requirements, equipment, and the chosen production process.
---
Why the cost is so variable
| Factor | How it influences cost | Typical impact |
|--------|------------------------|----------------|
| Facility size | Larger footprint = more land, building, utilities, and HVAC. | 1.5–3× increase per 10 k sq‑ft |
| GMP requirements | More stringent cleanrooms, validation, documentation, and environmental monitoring. | 20–40 % higher than non‑GMP |
| Process complexity | Lurasidone is a complex molecule requiring multistep synthesis, chiral resolution, and purification. | Need for specialized reactors, chromatography, and scale‑up equipment |
| Location | Land cost, local labor, energy prices, and regulatory overhead differ by region (USA, EU, Asia). | 30–60 % variation |
| Regulatory & compliance | FDA (or EMA, PMDA) inspections, GMP audits, and facility licensing. | Extra capital for documentation systems, QA labs, and audit trails |
| Utilities & infrastructure | Water, electricity, compressed air, steam, and waste‑treatment systems. | 10–20 % of total cost |
| Project management & contingencies | Unexpected delays, design changes, or supply‑chain disruptions. | 15–25 % of baseline cost |
---
Rough cost benchmarks
| Facility type | Typical cost (US$) | Comments |
|---------------|--------------------|----------|
| Small GMP lab / pilot plant (0.5–1 k L production) | $5–15 M | Good for early‑stage research, process optimization. |
| Mid‑size GMP production line (10–20 k L) | $20–60 M | Common for commercial launch of a single drug. |
| Large integrated plant (≥50 k L, multiple product lines) | $100–250 M+ | Multi‑drug facilities, high‑throughput synthesis. |
Lurasidone, being a complex, chiral molecule, would likely fall in the mid‑size to large category, especially if a single‑source plant is desired for global supply. Thus, a ballpark figure of $70 M–$150 M is typical for a dedicated, GMP‑compliant manufacturing site.
---
What the industry actually discloses
- Public filings (e.g., SEC 10‑K, 20‑F) sometimes mention “capital expenditures” for plant development but rarely break them down by product.
- Annual reports of companies that own Lurasidone (e.g., Johnson & Johnson, Janssen, or Eli Lilly) may note major “manufacturing expansion” projects, but the exact cost is usually confidential.
- Industry analysts (e.g., EvaluatePharma, PhRMA, IQVIA) provide average cost ranges for new drug facilities but not product‑specific numbers.
---
Bottom line
- Estimated cost: $50 M–$200 M (mid‑size to large, GMP‑grade plant).
- Key drivers: scale, process complexity, location, regulatory rigor.
- Proprietary details: Exact figures are typically confidential and not publicly released by the manufacturer.
If you need a more precise estimate for a specific project, you would normally engage a pharmaceutical engineering consultant who can factor in your exact production specifications, regulatory environment, and local construction costs.